American College of Cardiology

CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension

Retrieved on: 
Lundi, novembre 7, 2022
GLOBE, American College of Cardiology, Renin, Death, Adult, M.D, U.S. Securities and Exchange Commission, The New England Journal of Medicine, CKD, Risk, American College, Plasma protein binding, Hypertension, Population, Degenerative disease, SEC, Annual report, Cardiology, Safety, Achievement, Time, Aldosterone, Patient, Primary aldosteronism, American Heart Association, Security (finance), Blood pressure, Kidney disease, COVID-19, Stroke, Pharmaceutical industry, Medicine, Collection

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced that detailed results from the Phase 2 BrigHtn trial evaluating the safety and efficacy of baxdrostat in treatment-resistant hypertension were published online today in the New England Journal of Medicine. Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase.

Key Points: 
  • Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase.
  • The clinical biomarker activity of aldosterone and renin provide mechanistic insight into how baxdrostat achieves selective blood pressure lowering effects with no impact on cortisol.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.
  • Its lead asset, baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer

Retrieved on: 
Lundi, novembre 7, 2022
CFO, American Heart Association, Disclosure, Company, Accounting, American College of Cardiology, Therapy, Amarin Corporation, Primary aldosteronism, Kidney disease, Time, American College, Cardiology, Risk, Degenerative disease, Certified Public Accountant, GLOBE, Hypertension, Population, Adult, Taro Pharmaceuticals, Ernst, Ernst & Young, COVID-19, LLP, Stroke, CKD, Death, Annual report, U.S. Securities and Exchange Commission, Aldosterone, Retirement, Security (finance), SEC, Achievement, Patient, Management, Pharmaceutical industry, Collection

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4.

Key Points: 
  • WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4.
  • He is replacing Terry Coelho who is retiring from her role as Executive Vice President, CFO and Chief Business Development Officer.
  • Mr. Kalbs experience includes six years as Chief Financial Officer for Amarin Corporation, a publicly traded, multinational cardiovascular focused pharmaceutical company.
  • Prior to Amarin, he worked for seven years at Taro Pharmaceuticals where he was the Chief Financial Officer and Chief Accounting Officer.

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Vendredi, novembre 4, 2022
American Heart Association, Blood pressure, G&A, CINC, Society, OLE, Population, Adult, SBP, Income, Research, Research and development, Annual report, U.S. Securities and Exchange Commission, ET, CMC, Aldosterone, R, SEC, Administration, Disclosure, American College, MAD, Congress, GLOBE, International Society, Mercury (element), IPO, Death, Security (finance), Patient, Units of paper quantity, American College of Cardiology, Primary aldosteronism, Risk, ESC, European Society of Cardiology, COVID-19, Plasma protein binding, AHA, Chemistry, Kidney disease, Investment, Time, Publication, Degenerative disease, Safety, Stroke, CKD, ASN, American Society of Nephrology, ISH, NASDAQ, Achievement, Pharmaceutical industry, Collection, Hypertension, Cardiology

We are thrilled with the positive topline data reported for baxdrostat in treatment-resistant hypertension earlier this quarter.

Key Points: 
  • We are thrilled with the positive topline data reported for baxdrostat in treatment-resistant hypertension earlier this quarter.
  • We look forward to providing an update once the HALO trial data has been unblinded and analyzed, which is anticipated before year-end 2022.
  • In August 2022, CinCor reported positive topline data for the Phase 2 BrigHtn trial evaluating baxdrostat for patients with rHTN.
  • In October, CinCor announced the publication of the Phase 1 Multiple Ascending Dose Study Data in the journal, Hypertension Research.

CinCor Reports Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Jeudi, novembre 3, 2022
American Heart Association, Blood pressure, G&A, CINC, Society, OLE, Population, Adult, SBP, Income, Research, Research and development, Annual report, U.S. Securities and Exchange Commission, CMC, Aldosterone, R, SEC, Administration, Disclosure, American College, MAD, Congress, GLOBE, International Society, Mercury (element), IPO, Death, Security (finance), Patient, Units of paper quantity, American College of Cardiology, Primary aldosteronism, Risk, ESC, European Society of Cardiology, COVID-19, Plasma protein binding, AHA, Chemistry, Kidney disease, Investment, Time, Publication, Degenerative disease, HALO, Safety, Stroke, CKD, ASN, American Society of Nephrology, ISH, NASDAQ, Achievement, Pharmaceutical industry, Collection, Hypertension, Cardiology

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • We are thrilled with the positive topline data reported for baxdrostat in treatment-resistant hypertension earlier this quarter.
  • In August 2022, CinCor reported positive topline data for the Phase 2 BrigHtn trial evaluating baxdrostat for patients with rHTN.
  • In October, CinCor announced the publication of the Phase 1 Multiple Ascending Dose Study Data in the journal, Hypertension Research.
  • CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate for Predicting Major Cardiac Events in Patients with Chronic Kidney Disease

Retrieved on: 
Jeudi, novembre 3, 2022
Cardiology, Technology, Health, General Health, Health Technology, Research, Software, Artificial Intelligence, Hospitals, Science, Clinical Trials, American Heart Association, Public health, Company, Journal, HART, Arrest, Heart, Machine learning, Medicare, International Journal of Cardiology, CVE, AI, Congress, Chronic kidney disease, Principal, Biomarker, Open heart, Clinical Cardiology, Stroke, AUC, Algorithm, Centers for Disease Control and Prevention, Center, Massachusetts General Hospital, European Society of Cardiology, Canadian International Council, CKD, Artificial intelligence, The American Journal of Cardiology, Hospital, Kidney disease, Harvard Medical School, Risk, Cardiovascular disease, American College of Cardiology, AHA, Patient, MD, European Journal of Preventive Cardiology, Medical device, Cardiology, Medicine

Researchers from Massachusetts General Hospital tested 446 CKD patients undergoing coronary or peripheral angiography to predict two-year risk of heart attack, stroke, or cardiovascular death.

Key Points: 
  • Researchers from Massachusetts General Hospital tested 446 CKD patients undergoing coronary or peripheral angiography to predict two-year risk of heart attack, stroke, or cardiovascular death.
  • This accuracy across the different stages is important given a sharp increase in cardiovascular event risk as patients progressively decline in kidney function.
  • This HART CVE application is valuable for both hospitalized and outpatient chronic kidney patients.
  • In addition to the HART CVE test for risk of major cardiac events, Prevencio offers a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries.

ChristianaCare Creates Business Health Solutions to Offer Its Award-Winning Health Care Services to Employers Regionally and Nationally

Retrieved on: 
Mercredi, novembre 2, 2022
News, Heart, Population, Health, Hospital, Business development, Center, U.S. News & World Report, NPS, American College of Cardiology, GLOBE, Industry, COVID-19, Program, Computerworld, Cardiothoracic surgery, Business, Workforce, Healthgrades, Vaccination, American College, Forbes, Bariatric surgery, Clinical Excellence Awards, Patient, Hysterectomy, The Last Best Place, IDG, Bed, Society, Cardiology, Health insurance, Medicine, Pharmaceutical industry, Newsweek

ChristianaCare Business Health Solutions leverages the nationally recognized clinical expertise of ChristianaCare to provide high-quality, cost-effective health care services to businesses and employers, said Joe Miralles, vice president of Business Development at ChristianaCare.

Key Points: 
  • ChristianaCare Business Health Solutions leverages the nationally recognized clinical expertise of ChristianaCare to provide high-quality, cost-effective health care services to businesses and employers, said Joe Miralles, vice president of Business Development at ChristianaCare.
  • We offer direct-to-employer packages to keep health care costs down, improve employee wellness and workforce productivity and integrate services to offer accessible, high-quality, convenient care through enhanced coordination.
  • Headquartered in Wilmington, Delaware, ChristianaCare is one of the countrys most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs.
  • With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care.

Myia Health Collaborates with DispatchHealth to Empower Clinicians with Virtual Care Platform for Continuous Patient Monitoring

Retrieved on: 
Mercredi, novembre 2, 2022
Advance care planning, Internet access, CEO, Mercy Virtual, Health, Partnership, American College of Cardiology, GLOBE, Industry, Economics, American College, Patient, Machine learning, Myia, SAN, Solution, Medical imaging, Medicine, Hospital

Myias platform is part of our suite of capabilities that arms our clinicians to better take care of our patients.

Key Points: 
  • Myias platform is part of our suite of capabilities that arms our clinicians to better take care of our patients.
  • The continuous insights help us understand which patients need care when so we can optimize and expand our clinical offering.
  • Myia Health is the only comprehensive virtual care management and remote monitoring platform that optimizes patient outcomes, clinical operations, and the economics of healthcare delivery in the home.
  • Founded in 2017, the Myia platform powers the worlds first and largest virtual hospital, Mercy Virtual.

ChromaDex Corporation Reports Third Quarter 2022 Financial Results

Retrieved on: 
Mercredi, novembre 2, 2022
Research, Seniors, Genetics, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Science, Security (finance), Marketing, Growth, Face, Annual report, Securities Exchange Act of 1934, EBITDA, Clinical trial, Human body, U.S. Securities and Exchange Commission, News, Heart failure, Conference, SEC, Income, ChromaDex, American College of Cardiology, Research, COVID-19, Securities Act of 1933, Ageing, Human, Replay, BlueHat, Investor relations, American College, Investment, NASDAQ, Company, Tru, History, NAD, Patient, Compte rendu, Webcast, NR, GAAP, Phytochemical, Forward-looking statement, JACC, JV, NHNE, Video game, Grocery store, Pharmaceutical industry, Reinsurance, Bookkeeping, Communications satellite, Air cargo

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022.
  • Total net sales were $17.1 million, with $14.6 million from Tru Niagen, down (1)% each from the prior year quarter.
  • Net loss was $1.0 million or $(0.01) per share, an improvement of $0.12 per share from the prior year quarter.
  • We approached cash flow break even in the third quarter and remain on track to achieve this important objective next quarter, said ChromaDex CEO, Rob Fried.

MiCare Path Joins the Innovators' Network at American Heart Association (AHA) Center for Health Technology & Innovation and Will Integrate AHA Digital Science-Based CarePlans into Its Platform

Retrieved on: 
Mercredi, novembre 2, 2022
Online, American Heart Association, MPH, 2009 Davis Cup, FRCPE, Organization, NIH, MHealth, Department, FESC, Hospital, Man, FAHA, American College of Cardiology, Center, Solution, Science, Risk, Korea Disease Control and Prevention Agency, CEO, Stanford University, Health, Partnership, Collaborative innovation network, Division, Blood pressure, National Center for Health Statistics, Technology, Degenerative disease, AHA, Health education, Innovation, Patient, Multimedia, CDC, Le Bonheur Children's Hospital, Sleep, Diet, Physician, Centers for Disease Control and Prevention, St. Jude Children's Research Hospital, Volunteering, Woman, FAAP, Annals of Pediatric Cardiology, National, Tablet, Death, Cholesterol, Adult, FACC, GA, Medicine, Blood, Association, Medical statistics, Medical device, Pharmaceutical industry, MD, Cardiology, Network, Facebook

MEMPHIS, Tenn., Nov. 2, 2022 /PRNewswire/ -- MiCare Path, a platform that optimizes patient care through remote patient monitoring, has joined the AHA for Health Technology & Innovation's Innovators' Network (the Center). The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. MiCare Path will utilize CarePlans and digital science to deliver the future of healthcare, today.

Key Points: 
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • MiCare Path will utilize CarePlans and digital science to deliver the future of healthcare, today.
  • Innovators' Network members also have access to the Association's digital guidelines, recommendations and premier science as they develop digital healthcare technologies.
  • The National Institutes of Health (NIH) defines mHealth as: the use of mobile and wireless devices (cell phones, tablets, etc.)

CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming American Society of Nephrology Kidney Week 2022

Retrieved on: 
Mardi, octobre 25, 2022
U.S. Securities and Exchange Commission, Time, ASN, Hypertension, Risk, SEC, Chronic kidney disease, Kidney, Population, Achievement, Stroke, Annual report, NASDAQ, Society, Cardiology, Patient, Degenerative disease, Primary aldosteronism, Security (finance), Aldosterone, American College of Cardiology, Kidney disease, Pharmacokinetics, Death, Adult, American Heart Association, Safety, CINC, GLOBE, American College, COVID-19, American Society of Nephrology, Pharmaceutical industry, Collection

WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of a poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2022 taking place November 3-6, 2022, in Orlando, Florida.

Key Points: 
  • WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of a poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2022 taking place November 3-6, 2022, in Orlando, Florida.
  • The presentation will include clinical data from a Phase 1 open-label trial assessing the safety and pharmacokinetics of baxdrostat in subjects with varying degrees of renal function.
  • Hypertension and chronic kidney disease are common comorbidities that are exacerbated by elevated aldosterone levels.
  • Baxdrostat is currently being evaluated in patients with uncontrolled hypertension and chronic kidney disease as part of the Phase 2 figHTN-CKD trial.